JP5416971B2 - Ｃｄ３６の発現を減少させる方法 - Google Patents

Ｃｄ３６の発現を減少させる方法 Download PDF

Info

Publication number
JP5416971B2
JP5416971B2 JP2008531412A JP2008531412A JP5416971B2 JP 5416971 B2 JP5416971 B2 JP 5416971B2 JP 2008531412 A JP2008531412 A JP 2008531412A JP 2008531412 A JP2008531412 A JP 2008531412A JP 5416971 B2 JP5416971 B2 JP 5416971B2
Authority
JP
Japan
Prior art keywords
peptide
arg
phe
expression
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008531412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509941A (ja
JP2009509941A5 (OSRAM
Inventor
ヘイゼル エイチ セトー
シャオイ リウ
スンギー チョー
Original Assignee
コーネル リサーチ ファウンデイション インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル リサーチ ファウンデイション インコーポレイテッド filed Critical コーネル リサーチ ファウンデイション インコーポレイテッド
Publication of JP2009509941A publication Critical patent/JP2009509941A/ja
Publication of JP2009509941A5 publication Critical patent/JP2009509941A5/ja
Application granted granted Critical
Publication of JP5416971B2 publication Critical patent/JP5416971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
JP2008531412A 2005-09-16 2006-09-18 Ｃｄ３６の発現を減少させる方法 Active JP5416971B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71817005P 2005-09-16 2005-09-16
US60/718,170 2005-09-16
PCT/US2006/036291 WO2007035640A2 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012181082A Division JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Division JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法

Publications (3)

Publication Number Publication Date
JP2009509941A JP2009509941A (ja) 2009-03-12
JP2009509941A5 JP2009509941A5 (OSRAM) 2009-10-01
JP5416971B2 true JP5416971B2 (ja) 2014-02-12

Family

ID=37889419

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2008531412A Active JP5416971B2 (ja) 2005-09-16 2006-09-18 Ｃｄ３６の発現を減少させる方法
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Ｃｄ３６の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Ｃｄ３６の発現を減少させる方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Ｃｄ３６の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Ｃｄ３６の発現を減少させる方法

Country Status (10)

Country Link
US (10) US7541340B2 (OSRAM)
EP (5) EP3260127B1 (OSRAM)
JP (6) JP5416971B2 (OSRAM)
KR (9) KR101426070B1 (OSRAM)
CN (6) CN107412723A (OSRAM)
AU (1) AU2006292352B2 (OSRAM)
CA (8) CA2947343C (OSRAM)
DK (1) DK1931369T3 (OSRAM)
HK (1) HK1206971A1 (OSRAM)
WO (1) WO2007035640A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012233005A (ja) * 2005-09-16 2012-11-29 Cornell Research Foundation Inc Ｃｄ３６の発現を減少させる方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
US7704954B2 (en) 2003-05-01 2010-04-27 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7687243B1 (en) * 2005-06-06 2010-03-30 Crook Tonia M Automated method for detecting apoptosis in cells
PT2252312E (pt) * 2008-02-07 2014-07-17 Univ Cornell Métodos de prevenção ou tratamento de resistência a insulina
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
SMT202300433T1 (it) 2009-08-24 2024-01-10 Stealth Biotherapeutics Inc Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
CA2786280A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
AU2010339414A1 (en) * 2009-12-31 2012-07-19 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN103037901B (zh) * 2010-06-01 2018-04-27 康奈尔大学 抑制cd36以控制肥胖和胰岛素敏感性
EP3539554A1 (en) * 2010-07-09 2019-09-18 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2013149172A1 (en) * 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
CN105051534B (zh) * 2012-12-18 2017-08-18 佰鸥科瑞公司 用于治疗和/或限制糖尿病发展的方法
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
CA2925757A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
WO2015089316A1 (en) * 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
EP3082838A4 (en) * 2013-12-16 2017-07-26 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US11392555B2 (en) 2019-05-15 2022-07-19 Pure Storage, Inc. Cloud-based file services
WO2021021452A1 (en) * 2019-07-26 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University 1,8-cineol coated implants
CN115279394A (zh) 2019-11-20 2022-11-01 斯坦福大学托管董事会 用于放射治疗的预防性皮肤治疗
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2085865T3 (es) * 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
FR2756284B1 (fr) * 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JP2002505077A (ja) * 1997-12-10 2002-02-19 ワシントン大学 抗病原体システムおよびその使用方法
EP1071414A1 (en) * 1998-04-24 2001-01-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6503713B1 (en) * 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
DE10051983A1 (de) 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
ATE406908T1 (de) * 2000-10-20 2008-09-15 Hamburger Stiftung Zur Foerder Oxidierte proteine und deren biologische und therapeutische aktivität sowie diagnostische verwendung über die hemmung der interaktion zwischen oxidierten proteinen und cd36
US20040115261A1 (en) 2001-04-05 2004-06-17 Ashley Robert A. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
AU2002360460A1 (en) * 2001-12-03 2003-06-17 Nuvelo, Inc. Methods and materials relating to novel polypeptides and polynucleotides
JP4346870B2 (ja) * 2002-07-05 2009-10-21 キッコーマン株式会社 血糖値上昇抑制用組成物
US7785567B2 (en) * 2002-08-23 2010-08-31 Valorisation-Recherche, Société en Commandite Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US7704954B2 (en) * 2003-05-01 2010-04-27 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
US20050012597A1 (en) 2003-07-02 2005-01-20 Anderson Peter Traneus Wireless electromagnetic tracking system using a nonlinear passive transponder
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
CN1913774A (zh) * 2003-12-12 2007-02-14 独立行政法人科学技术振兴机构 表达MEGSIN/RAGE/iNOS的疾病模型动物及借助于该动物评估化合物的方法
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US8157123B2 (en) * 2005-02-23 2012-04-17 The Glad Products Company Container
CA2947343C (en) * 2005-09-16 2019-04-30 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
PT2252312E (pt) * 2008-02-07 2014-07-17 Univ Cornell Métodos de prevenção ou tratamento de resistência a insulina
CN107802821A (zh) 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
JP2012181082A (ja) * 2011-03-01 2012-09-20 Tokyo Electric Power Co Inc:The 仕切弁の分解点検補助装置およびその案内治具、並びに仕切弁の分解点検方法
CN202756379U (zh) 2012-07-13 2013-02-27 滨中元川金属制品（昆山）有限公司 一种自攻牙螺丝

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012233005A (ja) * 2005-09-16 2012-11-29 Cornell Research Foundation Inc Ｃｄ３６の発現を減少させる方法

Also Published As

Publication number Publication date
KR101426070B1 (ko) 2014-08-01
JP5809649B2 (ja) 2015-11-11
CA2947335A1 (en) 2007-03-29
JP2015164953A (ja) 2015-09-17
AU2006292352A1 (en) 2007-03-29
CA2947340C (en) 2019-05-07
CN104788540A (zh) 2015-07-22
CN104324360A (zh) 2015-02-04
HK1212718A1 (zh) 2016-06-17
CA2947343C (en) 2019-04-30
CA2947330A1 (en) 2007-03-29
US8603971B2 (en) 2013-12-10
KR101621493B1 (ko) 2016-05-16
KR20140042940A (ko) 2014-04-07
CA2947341C (en) 2019-03-05
CN102552874A (zh) 2012-07-11
US20250263433A1 (en) 2025-08-21
WO2007035640A3 (en) 2007-11-22
JP6385476B2 (ja) 2018-09-05
US20140256620A1 (en) 2014-09-11
CA2947328A1 (en) 2007-03-29
HK1173367A1 (en) 2013-05-16
US11447523B2 (en) 2022-09-20
EP3260127A1 (en) 2017-12-27
US20070129306A1 (en) 2007-06-07
DK1931369T3 (en) 2016-12-12
US20210047369A1 (en) 2021-02-18
JP2012233005A (ja) 2012-11-29
CN107412723A (zh) 2017-12-01
CA2947340A1 (en) 2007-03-29
JP2009509941A (ja) 2009-03-12
US20190248833A1 (en) 2019-08-15
KR20160057372A (ko) 2016-05-23
US20140249075A1 (en) 2014-09-04
JP6157539B2 (ja) 2017-07-05
KR20140106761A (ko) 2014-09-03
EP1931369A2 (en) 2008-06-18
KR20080050497A (ko) 2008-06-05
US7541340B2 (en) 2009-06-02
AU2006292352B2 (en) 2012-02-09
WO2007035640A2 (en) 2007-03-29
CN102552874B (zh) 2015-04-22
KR101999756B1 (ko) 2019-07-12
US7811987B2 (en) 2010-10-12
JP2017066161A (ja) 2017-04-06
US20090264369A1 (en) 2009-10-22
CN103784937B (zh) 2017-04-26
HK1206971A1 (en) 2016-01-22
JP2013075915A (ja) 2013-04-25
KR20150013353A (ko) 2015-02-04
CN103784937A (zh) 2014-05-14
CA2947333A1 (en) 2007-03-29
EP3549594A1 (en) 2019-10-09
CA2622911C (en) 2016-12-06
CN101296704B (zh) 2012-09-05
US9150614B2 (en) 2015-10-06
CN104788540B (zh) 2019-10-18
JP5805596B2 (ja) 2015-11-04
CA2947328C (en) 2019-03-05
US20100317571A1 (en) 2010-12-16
EP1931369B1 (en) 2016-08-17
KR20170105470A (ko) 2017-09-19
KR20160056863A (ko) 2016-05-20
KR20190084025A (ko) 2019-07-15
CA2947343A1 (en) 2007-03-29
CA2947341A1 (en) 2007-03-29
HK1123992A1 (en) 2009-07-03
US20170305967A1 (en) 2017-10-26
US20230212220A1 (en) 2023-07-06
EP3260127B1 (en) 2019-05-01
EP3095454A1 (en) 2016-11-23
JP6175107B2 (ja) 2017-08-02
KR20150013354A (ko) 2015-02-04
CA2947330C (en) 2018-06-05
CN101296704A (zh) 2008-10-29
CA2622911A1 (en) 2007-03-29
EP1931369A4 (en) 2012-05-02
JP2015205931A (ja) 2015-11-19
EP3725324A1 (en) 2020-10-21

Similar Documents

Publication Publication Date Title
JP6385476B2 (ja) Ｃｄ３６の発現を減少させる方法
AU2016203803B2 (en) Methods for reducing cd36 expression
AU2019257440A1 (en) Methods for reducing CD36 expression
HK1242610A1 (en) Methods for reducing cd36 expression
HK1197994B (en) Methods for reducing cd36 expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120518

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130131

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131118

R150 Certificate of patent or registration of utility model

Ref document number: 5416971

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250